Etanercept (Enbrel) — Clinical Policy
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PHAR.250 alerts
Get alerted when Policy MDN.CP.PHAR.250 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, prior authorization and continuation requirements for etanercept (Enbrel) for Meridian Health Plan Medicaid members across FDA‑approved indications and certain other uses.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Initial Approval — Ankylosing Spondylitis
Covered when ALL of the following are met:
ALL of the following
- Diagnosis of AS
- Age ≥ 18 years
- Prescriber: Prescribed by or in consultation with a rheumatologist
- Prior therapy: Failure of at least TWO non-steroidal anti-inflammatory drugs (NSAIDs) at up to maximally indicated doses, each used for ≥4 weeks unless clinically significant adverse effects are experienced or all are contraindicated
- Combination use: Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors
- Dose limit: Dose does not exceed 50 mg every week
inv-02: Initial Approval — Plaque Psoriasis
Covered when ALL of the following are met:
ALL of the following
- Diagnosis: Moderate-to-severe plaque psoriasis as evidenced by either ≥3% total body surface area OR involvement of hands, feet, scalp, face, or genital area
- Prescriber: Prescribed by or in consultation with a dermatologist or rheumatologist
- Age ≥ 4 years
- Prior therapy: Member meets one of: (a) failure of a ≥3 consecutive month trial of methotrexate at up to maximally indicated doses; (b) intolerance/contraindication to methotrexate and failure of a ≥3 month trial of cyclosporine at up to maximally indicated doses; (c) intolerance/contraindication to methotrexate and cyclosporine and failure of phototherapy
- Combination use: Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors
- Dose limit: Adults: 50 mg twice weekly for 3 months followed by maintenance 50 mg every week; Pediatrics: weight-based dosing — 0.8 mg/kg every week if <63 kg or 50 mg every week if ≥63 kg
inv-03: Initial Approval — Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Covered when ALL of the following are met:
ALL of the following
- Diagnosis of polyarticular juvenile idiopathic arthritis (PJIA) evidenced by ≥5 joints with active arthritis
- Prescriber: Prescribed by or in consultation with a rheumatologist
- Age ≥ 2 years
- Baseline assessment: Documented baseline 10-joint clinical juvenile arthritis disease activity score (cJADAS-10)
- Prior therapy: Member meets one of: (a) failure of a ≥3 consecutive month trial of methotrexate at up to maximally indicated doses; (b) intolerance/contraindication to methotrexate and failure of a ≥3 month trial of leflunomide or sulfasalazine; (c) for sacroiliitis/axial involvement, failure of a ≥4 week NSAID trial; (d) documented high disease activity with cJADAS-10 > 8.5
- Combination use: Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors
- Dose limit: Adults: 50 mg every week; Pediatrics: 0.8 mg/kg every week if <63 kg or 50 mg every week if ≥63 kg
inv-04: Initial Approval — Psoriatic Arthritis
Covered when ALL of the following are met:
ALL of the following
- Diagnosis of psoriatic arthritis (PsA)
- Prescriber: Prescribed by or in consultation with a dermatologist or rheumatologist
- Age ≥ 18 years
- Combination use: Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors
- Dose limit: Dose does not exceed 50 mg every week
inv-05: Initial Approval — Rheumatoid Arthritis
Covered when ALL of the following are met:
ALL of the following
- Diagnosis of rheumatoid arthritis (RA) per American College of Rheumatology (ACR) criteria
- Prescriber: Prescribed by or in consultation with a rheumatologist
- Age ≥ 18 years
- Prior therapy: Member meets one of: (a) failure of a ≥3 consecutive month trial of methotrexate at up to maximally indicated doses; (b) intolerance/contraindication to methotrexate and failure of a ≥3 consecutive month trial of at least ONE conventional DMARD (e.g., sulfasalazine, leflunomide, hydroxychloroquine)
- Baseline assessment: Documentation of baseline disease activity using CDAI or RAPID3 score
- Combination use: Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors
- Dose limit: Dose does not exceed 50 mg every week
inv-06: Other diagnoses/indications
Covered when ONE of the following is met:
ANY of the following
- Recent label change: If the drug underwent a label change within the last 6 months not yet reflected in this policy, follow the no-coverage or non-formulary policy depending on formulary status (CP.PMN.255 or CP.PMN.16)
- Off-label policy: If requested use is not listed in Section III and criterion 1 does not apply, refer to the off-label use policy CP.PMN.53
inv-07: Continued Therapy (All Indications)
Covered when ALL of the following are met:
ALL of the following
- Continuation eligibility: Member currently receiving medication via Centene benefit or previously met initial approval criteria, or continuity of care applies
- Response: Evidence of positive response: for RA a decrease in CDAI or RAPID3 from baseline (or RAPID3 substitution if CDAI cannot be performed); for pJIA a decrease in cJADAS-10 from baseline; for other indications clinician documents positive response
- Combination use: Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors
- Dose increase: If request is for dose increase, new dose must not exceed 50 mg every week
inv-08: Dosing by Indication
Dosing regimens for labeled indications (documented dosing must match indication/weight):
inv-09: Contraindications / Boxed Warnings
Patients must not be treated with etanercept if the following apply:
ANY of the following
- Contraindication: Patients with sepsis
- Boxed warnings for serious infections and malignancies
Requests for etanercept used in combination with other biologic disease-modifying antirheumatic drugs (bDMARDs), Janus kinase inhibitors (JAKi), anti‑CD20 monoclonal antibodies, selective co‑stimulation modulators, integrin receptor antagonists, interleukin agents, or other potent immunosuppressants are not authorized. These combinations are excluded because of additive immunosuppression and an increased risk of neutropenia and serious infections.
Non‑FDA‑approved indications that are not specifically addressed in this policy are excluded from coverage unless there is sufficient documentation of efficacy and safety in accordance with the Meridian off‑label use policy CP.PMN.53 or other evidence of coverage documents. Providers requesting coverage for off‑label uses must submit supporting clinical evidence per that off‑label policy.
Per Appendix D and the 2019 North American guidelines for hidradenitis suppurativa (HS), available evidence does not support the use of etanercept for HS. A randomized, double‑blind, placebo‑controlled study (n = 20) showed no statistically significant improvement, and other studies yielded mixed results; therefore etanercept is not supported for HS in this policy.
Use of etanercept in combination with other biologic DMARDs, JAK inhibitors, or potent immunosuppressants is considered not authorized and will be denied due to the risk of increased immunosuppression, neutropenia, and serious infections. Providers should not submit requests for concomitant biologic or targeted immunomodulatory therapy with etanercept.
Etanercept is contraindicated in patients with sepsis. Additionally, the policy highlights boxed warnings for serious infections and malignancies. There is limited or no evidence to support etanercept for hidradenitis suppurativa per the cited guideline and trials; such uses are not endorsed by this policy.
Initial Therapy Criteria
inv-30: Initial therapy — Initial approval criteria are indication‑specific and require specialty prescribing, age limits, prior therapy trials or documented intol...
Initial approval criteria are indication‑specific and require specialty prescribing, age limits, prior therapy trials or documented intolerance/contraindication, disease activity assessments where indicated, and dosing limits.
ALL of the following
- Specialty prescribing: Prescribed by or in consultation with a specialist (rheumatologist or dermatologist as specified by indication)
- Age limits: Age requirements vary by indication (e.g., RA/PsA/AS: ≥18 years; PJIA: ≥2 years; PsO: ≥4 years)
- Prior/conservative therapy: Required trials of conventional therapies as specified by indication (e.g., methotrexate ≥3 months for RA, PsO, PJIA; NSAID trials for AS/sacroiliitis) or documented intolerance/contraindication
- Disease activity assessments: Baseline disease activity scores required where indicated (CDAI or RAPID3 for RA; cJADAS-10 for PJIA)
- Combination use prohibition: No combination use with biological DMARDs or Janus kinase inhibitors
- Dose limits: Dosing must not exceed 50 mg per week unless otherwise specified by pediatric weight-based dosing
inv-31: Initial Therapy Dosing
Initial dosing per indication
ALL of the following
- RA initial dosing: 25 mg SC twice weekly or 50 mg SC once weekly
- PsO initial dosing (adult): 50 mg SC twice weekly for 3 months induction, then 50 mg SC once weekly maintenance
- PJIA pediatric dosing: Weight <63 kg: 0.8 mg/kg SC once weekly; Weight ≥63 kg: 50 mg SC once weekly
- AS/PsA dosing: 50 mg SC once weekly
Continuation and Maintenance Criteria
inv-32: Continuation therapy criteria
Continued therapy criteria for members already on etanercept:
ALL of the following
- Continuation eligibility: Member currently receiving medication via Centene benefit or previously met initial approval criteria, or continuity of care applies
- Response assessment: Objective or documented improvement: for RA a decrease in CDAI or RAPID3 from baseline (or RAPID3 substitution if CDAI cannot be performed); for pJIA a decrease in cJADAS-10 from baseline; for all other indications clinician documents positive response
- Combination use: Member does not have combination use with biological DMARDs or JAK inhibitors
- Dose cap: If request is for dose increase, new dose must not exceed 50 mg every week
Step Therapy Requirements
| Requirement | Details |
|---|---|
| Conservative therapy trial required | |
| Psoriasis, PJIA, and RA: documented failure of at least a 3‑month trial of methotrexate (MTX) at up to maximally indicated doses, unless intolerance/contraindication; alternatives (e.g., cyclosporine for PsO; leflunomide or sulfasalazine for PJIA; other conventional DMARD for RA) must be tried per indication details | |
| PJIA sacroiliitis/axial involvement | |
| For PJIA with sacroiliitis/axial spine involvement: failure of a ≥4‑week NSAID trial at up to maximally indicated doses unless contraindicated or clinically significant adverse effects | |
| Ankylosing spondylitis prior therapy | |
| AS: failure of at least TWO NSAIDs each used for ≥4 weeks (unless adverse effects or contraindicated) is required prior to approval | |
| Dose and prescriber requirements | |
| Prescribed by or in consultation with appropriate specialist (dermatologist or rheumatologist as indicated); dosing must not exceed the indication‑specific maximum (commonly 50 mg/week or specified induction regimens for PsO) |
| Requirement | Notes / Appendix B implication |
|---|---|
| Provider may need to document prior use of listed therapeutic alternatives | |
| Appendix B lists multiple alternative agents (nonbiologic DMARDs, TNF blockers, other biologics, and small molecules such as adalimumab and its biosimilars, apremilast, tofacitinib, etc.); documentation of prior use, intolerance, or contraindication to these agents may be requested when relevant to the indication | |
| No explicit linear step sequence provided | |
| Appendix B provides dosing regimens and agent lists but the policy does not mandate a specific ordered sequence of trials; instead providers should document prior use/failure or contraindication to appropriate alternatives per clinical judgment and appendix guidance |
Provider Actions and Documentation
Prior authorization required — show indication‑specific criteria
Prior authorization is required for etanercept (Enbrel); the provider must demonstrate that the member meets the indication‑specific initial approval criteria (see the per‑indication Initial Approval sections for required diagnosis, specialty prescriber, age, prior therapy trials or documented intolerance/contraindication, baseline assessments where applicable, and dosing limits).
Prior authorization and coding — HCPCS J1438 noted
When submitting a prior authorization for physician‑administered etanercept, reference applicable coding guidance; the policy lists HCPCS code J1438 (Injection, etanercept, 25 mg) as an informational code that may be used when the drug is administered under direct physician supervision.
- Codes in the policy are informational only; inclusion/exclusion of codes does not guarantee coverage.
Conservative therapy required before biologic — document trials/intolerance
Conservative therapy must be documented before approval for certain indications: for plaque psoriasis, RA, and PJIA the provider must document specified trials of conventional therapies (e.g., a ≥3‑month trial of methotrexate at maximally indicated doses unless intolerant/contraindicated; PJIA also allows leflunomide/sulfasalazine or an NSAID trial for sacroiliitis as specified).
- Psoriasis: failure of ≥3 months of MTX or MTX intolerance plus failed cyclosporine ≥3 months, or MTX/cyclosporine intolerance plus failed phototherapy (see Appendix D for MTX considerations).
- RA: failure of ≥3 months of MTX or MTX intolerance plus failure of ≥3 months of at least one conventional DMARD.
- PJIA: failure of ≥3 months of MTX or MTX intolerance plus failure of leflunomide/sulfasalazine ≥3 months; for sacroiliitis a ≥4 week NSAID trial is acceptable; high disease activity (cJADAS‑10 > 8.5) is an alternative.
Therapeutic alternatives — document alternatives/previous agents
Therapeutic alternatives are listed in Appendix B and include other TNF blockers (e.g., adalimumab and its biosimilars, infliximab and biosimilars, certolizumab, golimumab) and other biologic and non‑biologic DMARDs; providers should document prior use or failure of listed alternatives when applicable.
- Appendix B lists multiple alternative agents (including adalimumab and biosimilars) considered as therapeutic alternatives.
- The policy notes that providers may need to document prior use of alternative agents listed in Appendix B before authorization.
Required documentation — submit office notes, labs, prior therapy records
Submit supporting clinical documentation with the prior authorization request — e.g., office chart notes, laboratory results, baseline and follow‑up disease activity scores, and prior therapy records — to show the member has met all approval criteria.
- Examples include documentation of prior medication trials, rationale for intolerance/contraindication, and objective response measures (ESR/CRP, CDAI/RAPID3, cJADAS‑10).
Required clinical assessment tools — submit CDAI, RAPID3, cJADAS‑10, ACR criteria
Include disease activity assessments and classification criteria as supporting documentation: CDAI or RAPID3 for RA, cJADAS‑10 for polyarticular JIA, and ACR classification criteria where applicable are referenced in the policy appendices and must be provided as baseline (and follow‑up for continuation) assessments.
- CDAI (Appendix G) and RAPID3 (Appendix H) score requirements are listed for RA baseline assessment.
- cJADAS‑10 (Appendix I) is required as the baseline assessment for PJIA; thresholds (e.g., cJADAS‑10 > 8.5 for high disease activity) are provided.
Prohibited combination therapy — such combinations are not authorized
Combination therapy requests that add etanercept to other biologic DMARDs, JAK inhibitors, anti‑CD20 agents, co‑stimulation modulators, integrin receptor antagonists, or other potent immunosuppressants are not authorized and will be denied due to additive immunosuppression and infection risk.
- Policy III explicitly lists prohibited combinations (e.g., other TNF antagonists, IL inhibitors, JAK inhibitors, rituximab, Orencia, Entyvio).
Coding‑based denial risk — codes informational; verify coding prior to claims
Inclusion of a procedure or HCPCS code in this clinical policy does not guarantee coverage; providers should verify professional coding guidance before claim submission and note that J1438 is listed for physician‑administered etanercept only.
- Policy statement: “Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up‑to‑date sources of professional coding guidance prior to the submission of claims.”
- J1438 description: Injection, etanercept, 25 mg — may be used when drug is administered under direct physician supervision, not for self‑administered use.
Coding and Codes Referenced
| J1438 | Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered) |
Quantity Limits
Site of Care and Administration
Office/infusion administration — use J1438 when physician‑supervised
When the drug is administered under direct physician supervision (e.g., office or infusion setting), HCPCS code J1438 may be used; this code is not appropriate for self‑administered use.
- J1438 = Injection, etanercept, 25 mg (may be used for Medicare when administered under direct physician supervision; not for self‑administered use).
Biosimilar and Therapeutic Alternatives
Adalimumab and biosimilars listed as alternatives
Appendix B lists adalimumab and multiple biosimilars as therapeutic alternatives to etanercept; the policy does not state a mandatory preference or substitution requirement for adalimumab biosimilars.
Definitions and Assessment Tools
Background
Etanercept (Enbrel) is a tumor necrosis factor (TNF) blocker indicated for multiple inflammatory rheumatologic and dermatologic diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, chronic plaque psoriasis, and polyarticular juvenile idiopathic arthritis. Dosing guidance and indication‑specific criteria are provided in the policy appendices; maintenance dosing examples include 50 mg as a common adult regimen.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.